Preview

Ural Medical Journal

Advanced search

Analysis of the effectiveness of aspirin for the prevention of preeclampsia and alternative methods of prevention

https://doi.org/10.52420/2071-5943-2021-20-1-70-75

Abstract

Introduction. Preeclampsia is a hypertensive disorder of pregnancy that remains one of e leading causes of maternal and perinatal morbidity and mortality. The preventive strategy of prophylaxis with acetylsalicylic acid gives only a relative reduction in risk, and in a significant part of cases is ineffective. At the same time, the issue of preeclampsia prophylaxis is extremely relevant, since there are no effective methods for treating this condition, with the exception of the completion of gestation.

Purpose of the study. Based on the scientific literature, to evaluate the effectiveness of aspirin in the prevention of preeclampsia and to determine the possible reasons for the lack of effectiveness of such prevention.

Materials and methods. We conducted a search for scientific literature, as a result of which 39 sources were selected for the final scientific review (2010-2020). The PubMed, ResearchGate and Elibrary databases were used to search for scientific literature.

Results and discussion. The article presents a literature review of the analysis of the effectiveness of aspirin for the prevention of preeclampsia over the past 5 years, describes the mechanism of action of aspirin, presents studies that confirm or refute the effectiveness of aspirin depending on the dosage and gestational age. Potential alternative agents for the prevention of preeclampsia in cases of aspirin ineffectiveness have been reviewed.

Conclusion. Literature review data show that the effectiveness of aspirin for the prevention of preeclampsia depends on the chronobiological effect, compliance, gestational duration and dosage. It is necessary to continue research on the effectiveness of aspirin, and studies carried out on the Russian population will be of particular value for the Russian Federation.

About the Authors

E. V. Kudryavceva
Ural State Medical University
Russian Federation

Elena V. Kudryavtseva, PhD, associate professor

Ekaterinburg



V. V. Kovalev
Ural State Medical University
Russian Federation

Vladislav V. Kovalev, MD, PhD, Professor

Ekaterinburg



N. N. Bayazitova
Ural State Medical University
Russian Federation

Natalia N. Bayazitova

Ekaterinburg



N. M. Milyaeva
Ural State Medical University
Russian Federation

Natalia M. Milyaeva

Ekaterinburg



A. V. Kaumova
Ural State Medical University; Regional Children's Clinical Hospital, Regional perinatal center
Russian Federation

Alena V. Kaumova

Ekaterinburg



References

1. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. – 2019. – Vol. 133 (1). – P. e1-e25. – Doi: 10.1097/AOG.0000000000003018. PMID: 30575675.

2. Оленев, А. С. Преэклампсия как угрожающее жизни состояние / А. С. Оленев, В. А. Новикова, В. Е. Радзинский // Акушерство и гинекология. – 2020. – № 3. – С. 48-57.

3. Ганеева, А. В. Эффективность низких дз аспирина в профилактике преэклампсии у беременных группы риска с высокой вариабельностью артериального давления / А. В. Ганеева, Р. И. Габидуллина, С. Д. Маянская // ПМ. – 2019. – № 4.

4. Гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия. Клинические рекомендации (протокол лечения). –2016.

5. Aspirin vs Heparin for the Prevention of Preeclampsia / Katsi V., Kanellopoulou T., Makris T. [et al.] // Curr Hypertens Rep. – 2016. – Vol. 18 (7). – Р. 57. – Doi: 10.1007/s11906-016-0664-3. PMID: 27251704.

6. Antiplatelet agents for preventing pre-eclampsia and its complications / Duley L., Meher S., Hunter K. E. [et al.] // Cochrane Database Syst Rev. – 2019. – Vol. 2019 (10). – Р. CD004659. – Doi: 10.1002/14651858.CD004659.

7. Roberge, S. Meta-analysis on the effect of aspirin use for prevention of prelampsia on placental abruption and antepartum hemorrhage / S. Roberge, E. Bujold, K. H. Nicolaides // Am J Obstet Gynecol. – 2018. – Vol. 218 (5). – Р. 483-489. – Doi: 10.1016/j.ajog.2017.12.238.

8. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a metaanalysis / Bujold E., Roberge S., Lacasse Y. [et al.] // Obstet Gynecol. – 2010. – Vol. 116 (2 Pt 1). – 402-14. – Doi: 10.1097/AOG.0b013e3181e9322a. Р.

9. Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials / S. Roberge, B. Sibai, A. McCaw-Binns, E. Bujold // Am J Perinatol. – 2016. – Vol. 33 (8). – Р. 781-5. – Doi: 10.1055/s-0036-1572495.

10. The role of aspirin dose on the prevntion of preeclampsia and fetal growth restriction: systematic review and meta-analysis / Roberge S., Nicolaides K., Demers S. [et al.] // Am J Obstet Gynecol. – 2017. – Vol. 216 (2). – Р. 110-120.e6. – Doi: 01016/j.ajog.2016.09.076.

11. Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia / Wright D, Poon L.C., Rolnik D.L. [et al.] // Am J Obstet Gynecol. – 2017. – Vol. 217 (6). – Р. 685.e1-685.e5. – Doi: 10.1016/j.ajog.2017.08.110.

12. Roberge, SAspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis / S. Roberge, E. Bujold, K. H. Nicolaides // Am J Obstet Gynecol. – 2018. – Vol. 218 (3). – Р. 287-293.e1. – Doi: 10.1016/j.ajog.2017.11.561.

13. ASPRE trial: performance of screening for preterm pre-eclampsia / Rolnik D. L., Wright D., Poon L. C. Y. [et al.] // Ultrasound Obstet Gynecol. – 2017. – Vol. 50 (4). – Р. 492-495. – Doi: 10.1002/uog.18816.

14. Low-dose acetylsalicylic acid treatment modulates the production of cytokines and improves trophoblast function in an in vitro model of earlyonset preeclampsia / Panagodage S., Yong H. E., Da Silva Costa F. [et al.] // Am J Pathol. – 2016. – Vol. 186, № 12. – Р. 3217–3224.

15. The International Federation f Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention / Poon L. C., Shennan A., Hyett J. A. [et al.] // Int J Gynaecol Obstet. – 2019. – Vol. 145 (1). – Р. 1-33. – Doi: 10.1002/ijgo.12802.

16. Chaemsaithong, P.First trimester preeclampsia screening and prediction / P. Chaemsaithong, D. S. Sahota, L. C. Poon // Am J Obstet Gynecol. – 2020. – № 16. – Р. S0002-9378(20)30741-9. – Doi: 10.1016/j.ajog.2020.07.020.

17. Fantasia, H. C. Low-Dose Aspirin for the Prevention of Preeclampsia // Nurs Womens Health. – 2018. – Vol. 22 (1). – Р. 87-92– Doi: 10.1016/j.nwh.2017.12.002.

18. Преэклампсия и эклампсия: новые подходы к диагностике и оценке степени тяжести / Г. М. Савельева, Р. И. Шалина, А. Г. Коноплянников, М. А. Симухина // Акушерство и гинекология: новости, мнения, обучение. – 2018. – 6 (4). – 25–30. – Doi.org/10.24411/2303-9698-2018-14002.

19. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis / Brown M. C., Best K. E., Pearce M. S. [et al.] // Eur. J. Epidemiol. – 2013. – Vol. 28 (1). – Р. 1–19.

20. Aspirin alleviates endothelial gap junction dysfunction through inhibition of NLRP3 inflammasome activation in LPS-induced vascular injury/ Zhou X., Wu Y., Ye L. [et al.] // Acta Pharm Sin B. – 2019. – Vol. 9 (4). – Р. 711-723. – Doi: 10.1016/j.apsb.2019.02.008.

21. Aspirin and its pleiotropic application / Hybiak J., Broniarek I., Kiryczyński G. [et al.] // Eur J Pharmacol. – 2020. – Vol. 866. – Р. 172762. – Doi: 10.1016/j.ejphar.2019.172762.

22. Регистр лекарственных средств России : сайт. – Url: https://www.rlsnet.ru/tn_index_id_375.htm (дата обращения: 0206.2021).

23. Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 and/or COX-2 inhibition? / Mirabito Colafella K. M., Neuman R. I., Visser W. [et al.] // Basic Clin Pharmacol Toxicol. – 2020. – Vol. 127 (2). – Р. 132-141. – Doi: 10.1111/bcpt.13308.

24. Aspirin and its pleiotropic application / Hybiak J., Broniarek I., Kiryczyński G. [et al.] // Eur J Pharmacol. – 2020. – № 866. – Р. 172762. – Doi: 10.1016/j.ejphar.2019.172762.

25. Khalid, A. Aspirin In The Prevention Of Pre-Eclampsia: Where Are We Now? / A. Khalid, B. M. // Byrne Ir Med J. – 2018. – Vol. 111 (3). – Р. 704.

26. Das, U. N. Arachidonic acid in health and disease with focus on hypertension and diabetes mellitus: A review // J Adv Res. – 2018. – № 11. – Р. 43-55. – Doi: 10.1016/j.je.2018.01.002.

27. Disbalans vazoaktivnykh komponetov i arakhidonovoĭ kisloty v platsente i okoloplodnykh vodakh pri preéklampsii [The imbalance of vasoactive components and arachidonic acid in the placenta and amniotic fluid in preeclampsia] / Pogorelova T. N., Krukier I. I., Gunko V. O. [et al.] // Biomed Khim. – 2019. – Vol. 65 (3). – Р. 245-250. – Doi: 10.18097/PBMC20196503245.

28. Oxidative stress and mitochondrial dyfunction in early-onset and late-onset preeclampsia / Marín R., Chiarello D. I., Abad C. [et al.] // Biochim Biophys Acta Mol Basis Dis. – 2020. – Vol. 1866 (12). – Р. 165961. – Doi: 10.1016/j.bbadis.2020.165961.

29. Бобров, М. Ю. Внеклеточные везикулы и микроРНК: перспективные объекты исследования для понимания патогенеза преэклампсии // Medica mente. Лечим с умом. – 2016. – № 2. – С. 3-8.

30. Физиология и патология внеклеточных везикул / Пантелеев М. А., Абаева А. А., Нечипуренко Д. Ю. [и др.] // Онкогематология. – 2017. – № 1. – С. 62-70.

31. Роль взаимодействия экстраклеточных микровезикул трофобласта с клетками иммунной системы и эндотелия в патогенезе преэклампсии / Г. О. Керкешко, А. В. Кореневский, Д. И. Соколов, С. А. Сельков // Медицинская иммунология. – 2018. – № 4. – С. 485-514.

32. Aspirine et prééclampsie [Aspirin and preeclampsia] / Atallah A., Lecarpentier E., Goffinet F. [et al.] // Presse Med. – 2019. – Vol. 48 (1 Pt 1). – Р. 34-45. – Doi: 10.1016/j.lpm.2018.11.022.

33. Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis / D. Mallampati, W. Grobman, D. J. Rouse, E. F. Werner // Obstet Gynecol. – 2019. – Vol. 134 (3). – Р. 537-544. – Doi: 10.1097/AOG.0000000000003413.

34. Инициатива по преэклампсии международной федерации гинекологии и акушерства (FIGO) : практическое руководство по скринингу в I триместре и профилактике заболевания / Пун Л. К., Шеннан А., Хайет Дж. А. [и др.]; [адаптированная версия на русском языке под ред. З. С. Ходжаевой, Е. Л. Яроцкой, И. И. Баранова] // Акушерство и гинекология: новости, мнения, обучение. – 2019. – Vol. 4 (26). – Р. 32-60.

35. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspiin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history / Poon L. C., Wright D., Rolnik D. L. [et al.] // Am J Obstet Gynecol. – 2017. – Vol. 217 (5). – Р. 585.e1-585.e5. – Doi: 10.1016/j.ajog.2017.07.038.

36. Танашян, М. М. Аспиринорезистентность: клинические и молекулярно-генетические методики оценки / М. М. Танашян, М. А. Домашенко, А. А. Раскуражев // Анналы клинической и экспериментальной неврологии. – 2016. – № 1. – С. 41-46.

37. Суслина, З. А. Индивидуализация антиагрегантной терапии у пациентов с цереброваскулярными заболеваниями / З. А. Суслина, М. Манашян, М. А. Домаенко // Клиническая армакология и терапия. – 2011. – № 20 (5). – С. 70-74.

38. Кудрявцева, Е. В. Тромбофилии в акушерстве: от генотипа к фенотипу : учебное пособие для врачей / Е. В. Кудрявцева, В. В. Ковалев. – Екатеринбург : Из-во УГМУ, 2019. – 96 с.

39. Novel Interventions for the Prevention of Preeclampsia / M. Ma'ayeh, K. M. Rood, D. Kniss, M. M. Costantine // Curr Hypertens Rep. – 2020. – Vol. 22 (2). – Р. 17. – Doi: 10.1007/s11906-020-1026-8.


Review

For citations:


Kudryavceva EV, Kovalev VV, Bayazitova NN, Milyaeva NM, Kaumova AV. Analysis of the effectiveness of aspirin for the prevention of preeclampsia and alternative methods of prevention. Ural Medical Journal. 2021;20(1):70-75. (In Russ.) https://doi.org/10.52420/2071-5943-2021-20-1-70-75

Views: 604


ISSN 2071-5943 (Print)
ISSN 2949-4389 (Online)